July 31 Preclinical Quick Takes: Sangamo reveals new gene editors; plus a CRISPR prediction model and vaccine boosters for ischemia

Sangamo unveils next-gen ZFN editors
In a Nature Biotechnology study, Sangamo Therapeutics Inc. (NASDAQ:SGMO) reported a next generation zinc finger nuclease (ZFN) gene editing technology with amino acid substitutions

Read the full 288 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE